Gene Therapy for Spinal Muscular Atrophy: Patient Perspective on Clinical Trials and Impact

Time: 2:35 pm
day: Day Two


• Impact of gene therapy on the SMA patient population
• What really matters? Existing unmet need. How does the risk/benefit ratio differ from developer to patient?
• Informing future gene therapy development and focusing on important metrics